1. 164: PARIS: A phase I study of pembrolizumab anti-PD-1 monoclonal antibody in combination with radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC). (January 2017) Authors: Kordbacheh, T.; Chan, C.; Bossons, A.; Franks, K.; McDonald, F.; Forster, M.; Mendes, R.; Quezada, S.; Dovedi, S.; Ralph, C.; Popat, S.; Harrington, K.; Melcher, A.; Popple, A.; Illidge, T.; Faivre-Finn, C. Journal: Lung cancer Issue: Volume 103(2017)Supplement 1 Page Start: S75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 168: PD-RAD: A translational study investigating PD-L1 expression after radiotherapy for non-small cell lung cancer (NSCLC). (January 2017) Authors: Kordbacheh, T.; Chan, C.; Faivre-Finn, C.; Franks, K.; McDonald, F.; Forster, M.; Mendes, R.; Quezada, S.; Dovedi, S.; Ralph, C.; Popat, S.; Harrington, K.; Melcher, A.; Popple, A.; Illidge, T. Journal: Lung cancer Issue: Volume 103(2017)Supplement 1 Page Start: S78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A TLR7 agonist enhances the anti-tumour efficacy of obinutuzumab through an NK cell/CD4 dependent mechanism in a murine lymphoma model. (July 2016) Authors: Cheadle, E.; Lipowska-Bhalla, G.; Fagnano, E.; Klein, C.; Dovedi, S.; Honeychurch, J.; Illidge, T. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pre-treatment Lymphocytopaenia is a Valid Adverse Prognostic Factor in Muscle-invasive and Advanced Bladder Cancer. Issue 5 (May 2016) Authors: Joseph, N.; Thompson, C.; Dovedi, S.; Lyons, J.; Elliott, T.; Choudhury, A. Journal: Clinical oncology Issue: Volume 28:Issue 5(2016) Page Start: e11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗